Tags
abiraterone acetate ADT ai in healthcare alphafold androgen deprivation therapy antibody-drug conjugate apalutamide artificial intelligence bispecific antibody bone metastases cancer immunotherapy cancer treatment CAR-T castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide docetaxel drug discovery drug repurposing drug resistance enzalutamide hormone therapy immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC neuroendocrine prostate cancer oncology personalized medicine preclinical prostate cancer PSA response PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 survival outcomes T-cell therapy theranostics treatment resistance
Latest Posts
- Preclinical: NRM-823, a Breakthrough T-Cell Engager Targeting Advanced Prostate Cancer January 14, 2025
- RPT04402 Reactivating PP2A: A Different Approach in Advanced Prostate Cancer Therapy January 14, 2025
- Phase 1b Promising Results: ORIC-944, a PRC2 Inhibitor for Advanced Prostate Cancer January 14, 2025
- Results from Phase 3 Trial of CAN-2409: a Promising Immunotherapy for Prostate Cancer January 14, 2025